Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Tops Revenue Estimates

Group 1 - Adaptive Biotechnologies reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of$0.26, and improved from a loss of $0.30 per share a year ago, representing an earnings surprise of 11.54$47.46 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.23% and showing an increase from 45.78 million year-over-year [2] - Adaptive Biotechnologies has outperformed the S&P 500, with shares up about 28.1% since the beginning of the year compared to the S&P 500's gain of 3.1% [3] Group 2 - The earnings outlook for Adaptive Biotechnologies is mixed, with the current consensus EPS estimate for the coming quarter at -0.26 on revenues of $46.59 million, and -$0.92 on revenues of $210.4 million for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Adaptive Biotechnologies belongs, is currently ranked in the top 26% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]